Physician profile
Michael S Collier
NPI 1811933674
$16,656.19
in general payments reported to CMS, 2019-2025
74 companies · $2,216 in 2025
The $2,216 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,063 · 2020: $1,944 · 2021: $2,807 · 2022: $2,646 · 2023: $2,486 · 2024: $2,493 · 2025: $2,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,150 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,150.43 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,322.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,156.09 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,766.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,185.13 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $1,153.58 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $914.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $567.83 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.52 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $437.88 | 2020-2025 | Xifaxan |
| Amarin Pharma, INC. | $370.56 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $317.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $295.18 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $272.87 | 2023-2025 | Rexulti |
| Allergan, INC. | $260.47 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $234.74 | 2021-2025 | Gvoke Hypopen |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.